不同化疗方案治疗鼻腔NK/T细胞淋巴瘤的临床疗效对比分析  被引量:9

Comparison of Clinical Efficacy of Different Chemotherapy for Nasal NK/T-cell Lymphoma

在线阅读下载全文

作  者:杨凯[1] 何学鹏[1] 楼金星[1] 刘晓东[1] 郭智[1] 张媛[1] 陈鹏[1] 陈惠仁[1] 

机构地区:[1]北京军区总医院血液病科,100700

出  处:《实用癌症杂志》2015年第11期1625-1628,共4页The Practical Journal of Cancer

基  金:国家自然科学基金资助项目(编号:31300747)

摘  要:目的探索两种不同化疗方案治疗鼻腔NK/T细胞淋巴瘤的疗效及不良反应。方法 47例原发性鼻腔NK/T细胞淋巴瘤患者分为两组,其中13例接受含培门冬酶的SMILE方案化疗,34例接受包含左旋门冬酰胺酶标准SMILE方案化疗,定期监测所有患者血常规、肝功能、凝血功能、乳酸脱氢酶、血淀粉酶及血糖。结果培门冬酶方案化疗组完全缓解率和总有效率(61.5%和76.9%)高于左旋门冬酰胺酶方案化疗组(58.8%和70.6%),但差异无统计学意义(P>0.05)。两组不同化疗方案骨髓抑制情况及不良反应发生率比较差异无统计学意义(P>0.05)。结论应用培门冬酶的SMILE方案化疗是安全、有效的治疗措施,在未增加NK/T细胞淋巴瘤患者不良反应的情况下,可取得与标准SMILE化疗方案近似的疗效。Objective To explore the theapeutic effects and adverse reactions of 2 chemotherapy methods for nasal NK/ T-cell lymphoma. Methods 47 patients with nasal NK/T-cell lymphoma were divided into 2 groups, 13 cases received the chem- otherapy of smile regimen containing PEG-ASP,34 eases received the chemotherapy of standard smile regimen containing L-ASP. Laboratory tests, including hemogram, liver function, coagulation function, serum amylase, lactate dehydrogenase and blood glucose were used to detect regularly: Results The complete remission ratio and the total effective ratio were 61.5% and 76.9% , re- spectively, in the PEG-ASP group,which were much higher than those of the L-ASP group (58.8% and 70.6% ), but the above difference was not statistically significant(P 〉 0.05). There was no statistically difference in the myelosuppression and the inci- dence of adverse reactions between the 2 groups ( P 〉 0.05 ). Conclusion The chemotherapy of smile regimen of PEG-ASP for nasal NK/T-cell lymphomais safe and effective, without increase in adverse reactions,it can can obtain similar result as standard SMILE chemotherapy.

关 键 词:NK/T细胞淋巴瘤 培门冬酶 左旋门冬酰胺酶 疗效 

分 类 号:R733.4[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象